Ketogenic dietary intervention may inhibit onset and progression of neuroendocrine tumors

A recent Cell Death and Disease study evaluated the effect of ketogenic dietary intervention on neuroendocrine tumors.

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants – Psychedelic Alpha

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profile Pharmacokinetic and pharmacodynamic data confirmed systemic delivery of

October 3, 2023

BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer – Pharmaceutical Technology

The Opdivo/Yervoy combination was studied in the Phase III CheckMate-9DW study as a first-line treatment for hepatocellular carcinoma. Credits: HJBC/Shutterstock.com Bristol Myers Squibb has announced

July 19, 2024

Organigram Q3 Revenue Increases 25%

Organigram Reports Third Quarter Fiscal 2024 Results August 13, 2024 Net revenue of $41.1 million increased 25% over the prior year period Adjusted EBITDA¹ of

August 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.